dc.contributor.author | Hochhaus, Andreas | |
dc.contributor.author | Baccarani, Michele | |
dc.contributor.author | Silver, Richard T. | |
dc.contributor.author | Schiffer, Charles A. | |
dc.contributor.author | Apperley, Jane F. | |
dc.contributor.author | Cervantes, Francisco | |
dc.contributor.author | Clark, Richard E. | |
dc.contributor.author | Cortes, Jorge Eduardo | |
dc.contributor.author | Deininger, Michael Werner Nikolaus | |
dc.contributor.author | Guilhot, François | |
dc.contributor.author | Hjorth-Hansen, Henrik | |
dc.contributor.author | Hughes, Timothy Peter | |
dc.contributor.author | Janssen, Jeroen J.W.M. | |
dc.contributor.author | Kantarjian, Hagop M. | |
dc.contributor.author | Kim, Dong-Wook | |
dc.contributor.author | Larson, Richard A. | |
dc.contributor.author | Lipton, Jeffrey Howard | |
dc.contributor.author | Mahon, François-Xavier | |
dc.contributor.author | Mayer, Jiří | |
dc.contributor.author | Nicolini, Franck Emmanuel | |
dc.contributor.author | Niederwieser, Dietger Walter | |
dc.contributor.author | Pane, Fabrizio | |
dc.contributor.author | Radich, Jerald P. | |
dc.contributor.author | Réa, Delphine | |
dc.contributor.author | Richter, Johan | |
dc.contributor.author | Rosti, Gianantonio | |
dc.contributor.author | Rousselot, Philippe | |
dc.contributor.author | Saglio, Giuseppe | |
dc.contributor.author | Saußele, Susanne | |
dc.contributor.author | Soverini, Simona | |
dc.contributor.author | Steegmann, Juan Luis | |
dc.contributor.author | Turkina, Anna | |
dc.contributor.author | Zaritskey, Andrey Yu. | |
dc.contributor.author | Hehlmann, Rüediger | |
dc.date.accessioned | 2021-01-07T11:45:37Z | |
dc.date.available | 2021-01-07T11:45:37Z | |
dc.date.created | 2020-04-30T13:35:55Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Leukemia. 2020, 34 (4), 966-984. | en_US |
dc.identifier.issn | 0887-6924 | |
dc.identifier.uri | https://hdl.handle.net/11250/2722001 | |
dc.description.abstract | The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% BCR-ABL1 at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer Nature | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 966-984 | en_US |
dc.source.volume | 34 | en_US |
dc.source.journal | Leukemia | en_US |
dc.source.issue | 4 | en_US |
dc.identifier.doi | 10.1038/s41375-020-0776-2 | |
dc.identifier.cristin | 1808875 | |
dc.description.localcode | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/. | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |